Ligand-based rational design, synthesis and evaluation of novel potential chemical chaperones for opsin

Eur J Med Chem. 2021 Dec 15:226:113841. doi: 10.1016/j.ejmech.2021.113841. Epub 2021 Sep 17.

Abstract

Inherited blinding diseases retinitis pigmentosa (RP) and a subset of Leber's congenital amaurosis (LCA) are caused by the misfolding and mistrafficking of rhodopsin molecules, which aggregate and accumulate in the endoplasmic reticulum (ER), leading to photoreceptor cell death. One potential therapeutic strategy to prevent the loss of photoreceptors in these conditions is to identify opsin-binding compounds that act as chemical chaperones for opsin, aiding its proper folding and trafficking to the outer cell membrane. Aiming to identify novel compounds with such effect, a rational ligand-based approach was applied to the structure of the visual pigment chromophore, 11-cis-retinal, and its locked analogue 11-cis-6mr-retinal. Following molecular docking studies on the main chromophore binding site of rhodopsin, 49 novel compounds were synthesized according to optimized one-to seven-step synthetic routes. These agents were evaluated for their ability to compete for the chromophore binding site of opsin, and their capacity to increase the trafficking of the P23H opsin mutant from the ER to the cell membrane. Different new molecules displayed an effect in at least one assay, acting either as chemical chaperones or as stabilizers of the 9-cis-retinal-rhodopsin complex. These compounds could provide the basis to develop novel therapeutics for RP and LCA.

Keywords: Molecular modelling; Rhodopsin; Severe inherited blinding diseases; Small-molecule agents; Synthetic organic chemistry.

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Design*
  • Humans
  • Leber Congenital Amaurosis / drug therapy*
  • Leber Congenital Amaurosis / metabolism
  • Ligands
  • Molecular Chaperones / chemical synthesis
  • Molecular Chaperones / chemistry
  • Molecular Chaperones / pharmacology*
  • Molecular Docking Simulation
  • Molecular Structure
  • Opsins / antagonists & inhibitors*
  • Opsins / metabolism
  • Retinitis Pigmentosa / drug therapy*
  • Retinitis Pigmentosa / metabolism
  • Structure-Activity Relationship

Substances

  • Ligands
  • Molecular Chaperones
  • Opsins